Carlsmed Leads Surgical Instrument Makers in Personalized Spine Solutions

Got story updates? Submit your updates here. ›

Carlsmed (NASDAQ:CARL) is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions. Its aprevo Technology Platform, which includes custom-designed interbody implants and surgical instruments, has shown favorable results in achieving proper post-operative spinal alignment and reducing the need for revision surgeries compared to traditional spine fusion procedures. Carlsmed is currently focused on the U.S. market but plans to expand internationally, and is also developing its platform for cervical spine fusion surgeries.

Why it matters

Carlsmed's personalized approach to spine surgery aims to address the limitations of traditional fusion procedures, which often lack robust pre-operative planning and use one-size-fits-all implants that fail to match each patient's unique anatomy. This can lead to poor alignment and increased risk of revision surgery, imposing significant health and economic burdens. Carlsmed's technology represents a potential solution to improve patient outcomes and reduce healthcare costs.

The details

Carlsmed's aprevo Technology Platform utilizes AI-enabled software to develop personalized digital surgical plans and custom-designed interbody implants for each patient. This aims to achieve proper spinal alignment and reduce the likelihood of revision surgery, which can occur in 14-32% of cases with traditional fusion procedures. Carlsmed's platform is FDA-cleared for lumbar fusion and the company expects to commercialize it for cervical fusion in 2026, pending additional clearances. Carlsmed currently has 199 surgeon users who have completed procedures with the aprevo Technology Platform, up from 116 a year earlier.

• Carlsmed received FDA 510(k) clearance for its aprevo interbody implants for cervical interbody fusion surgeries in November 2024.
• Carlsmed plans to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026, assuming it receives the necessary additional clearances.

What’s next

Carlsmed plans to continue building out its aprevo Technology Platform for cervical fusion procedures by pursuing additional FDA clearances for advancements to its cervical software platform and personalized plating solutions.